Anti-VEGFR-2 monoclonal antibody
US11370834B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2018 |
| Grant date | Jun 28, 2022 |
| Priority date | — |
| Expiry date | Oct 17, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application belongs to the technical field of biomedicines and provides an improved anti-Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) monoclonal antibody and an application thereof. By a computer-aided simulation design, a novel phage antibody library is designed, and an improved anti-VEGFR-2 monoclonal antibody is obtained after multiple rounds of screening. Both affinity and biological activity of the antibody are higher than those of an original antibody. The antibody is capable of effectively inhibiting combination of VEGFR-2 and a ligand Vascular Endothelial Growth Factor (VEGF) thereof in vitro, and may be used in treating a tumor and a disease caused by angiogenesis such as macular degeneration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.